Pfizer, BioNTech objection to CureVac's new arguments referred to US magistrate
The addition of eight new secondary considerations of nonobviousness by patent owner CureVac two months after the close of fact discovery and five months before trial is “procedural chicanery,” infringement defendants...To view the full article, register now.
Already a subscriber? Click here to view full article